These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34006960)

  • 1. Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.
    Kshatri JS; Bhattacharya D; Kanungo S; Giri S; Palo SK; Parai D; Turuk J; Mansingh A; Choudhary HR; Pattnaik M; Dash GC; Mohanty P; Mishra N; Satapathy DM; Sahoo SK; Pati S;
    Sci Rep; 2021 May; 11(1):10551. PubMed ID: 34006960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys.
    Kshatri JS; Bhattacharya D; Praharaj I; Mansingh A; Parai D; Kanungo S; Palo SK; Giri S; Pattnaik M; Barik SR; Dash GC; Choudhary HR; Turuk J; Mandal NN; Pati S
    Epidemiol Infect; 2021 Apr; 149():e139. PubMed ID: 33902776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serosurveys to detect SARS-CoV-2 antibodies among high-risk groups in six urban cities of Odisha, India.
    Kanungo S; Giri S; Bhattacharya D; Kshatri JS; Palo SK; Parai D; Turuk J; Praharaj I; Mansingh A; Dash GC; Choudhary HR; Pattnaik M; Barik SR; Mohanta AR; Swain A; Mohapatra I; Sahoo RK; Mishra RP; Patro SK; Satapathy DM; Pati S;
    J Infect Dev Ctries; 2023 Sep; 17(9):1255-1261. PubMed ID: 37824363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.
    Mahapatra A; Palo SK; Bhattacharya D; Kanungo S; Kshatri JS; Mishra BK; Mansingh A; Parai D; Pattnaik M; Choudhary HR; Dash GC; Mohanta AR; Bishoyee A; Mohanty P; Mandal N; Dayal R; Mitra A; Pati S
    Indian J Med Res; 2022 Aug; 156(2):228-239. PubMed ID: 36629182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: findings from serosurvey study in a rural cohort of eastern India.
    Dash P; Mansingh A; Nayak SR; Sahoo D; Bhattacharya D; Kanungo S; Kshatri JS; Mishra BK; Pattnaik M; Parai D; Choudhary HR; Nayak S; Rana K; Alice A; Sahoo AK; Mohanty KC; Mohanty P; Doley C; Jain H; Majhi D; Pattanayak P; Behuria S; Panda S; Bhoi S; Pati S; Palo SK
    Epidemiol Infect; 2022 Mar; 150():e58. PubMed ID: 35287778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological survey for SARS-CoV-2 antibodies among tribal communities of Odisha post-second wave.
    Kshatri JS; Bhattacharya D; Giri S; Palo SK; Kanungo S; Mansingh A; Parai D; Dany SS; Bisoyee A; Choudhary HR; Sinha A; Sahoo RK; Bhoi T; Mohanta AR; Ota AB; Mohanty B; Sahoo UK; Pati S
    Indian J Med Res; 2022 Aug; 156(2):284-290. PubMed ID: 36629188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 seroprevalence in healthcare workers in a high-volume ophthalmology centre in Guatemala.
    Davila-Siliezar P; Wer A; Barnoya J
    Ann Med; 2021 Dec; 53(1):1956-1959. PubMed ID: 34727801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020.
    Kar SS; Sarkar S; Murali S; Dhodapkar R; Joseph NM; Aggarwal R
    Emerg Infect Dis; 2021 Feb; 27(2):666-669. PubMed ID: 33496645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study.
    Barchuk A; Skougarevskiy D; Titaev K; Shirokov D; Raskina Y; Novkunkskaya A; Talantov P; Isaev A; Pomerantseva E; Zhikrivetskaya S; Barabanova L; Volkov V
    Sci Rep; 2021 Jun; 11(1):12930. PubMed ID: 34155259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.
    Basto-Abreu A; Carnalla M; Torres-Ibarra L; Romero-Martínez M; Martínez-Barnetche J; López-Martínez I; Aparicio-Antonio R; Shamah-Levy T; Alpuche-Aranda C; Rivera JA; Barrientos-Gutierrez T;
    Nat Commun; 2022 Feb; 13(1):589. PubMed ID: 35105873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India.
    Selvaraju S; Kumar MS; Thangaraj JWV; Bhatnagar T; Saravanakumar V; Kumar CPG; Sekar K; Ilayaperumal E; Sabarinathan R; Jagadeesan M; Hemalatha MS; Murhekar MV;
    Emerg Infect Dis; 2021 Feb; 27(2):586-589. PubMed ID: 33496222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.
    Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R
    BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.